Over the last 20 years, a trend towards regimens with less frequent dosing has been observed across medicine. Recent surveys of people with HIV indicate that there is a strong preference for once-daily dosing and compact therapy. Four antiretrovirals (tenofovir, didanosine, lamivudine and efavirenz) are now available as once-a-day therapies. The range of once-daily options is expanding rapidly, with the potential for two lines of once-daily therapy to be available in the next 12–18 months.
The AWARE Talk Radio Poll2001-2002. The AIDS Talk Radio Project in conjunction with The Core Center, AIDS Research Alliance [an internet survey].Chicago: Howard Brown Health Center
2.
MoyleG. The Appt-1 study: assessing patients’ preferred treatments [Abstract p 90]. HIV 6, Glasgow 2002
3.
BartlettJA, DeMasiR, QuinnJOverview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults.AIDS2001; 15: 136977
4.
ClaxtonAJ, CramerJ, PierceC. A systematic review of the associations between dose regimens and medication compliance.Clin Ther2001; 23: 1296310
5.
PatersonDL, SwindellsS, MohrJAdherence to protease inhibitor therapy and outcomes in patients with HIV infection.Ann Intern Med2000; 133: 2130
6.
VibhagoolA, CahnP, SchechterMAbacavir/Combivir (ABC/COM) is comparable to indinavir/Combivir (IDV/COM) in HIV-1 infected antiretroviral therapy naïve adults: preliminary results of a 48-week open-label study (CNA3014) [Abstract 63]. 1st International AIDS Society Conference, Buenos Aires 2001
7.
KatlamaC, on behalf of the Trizal European Study group. TRIZAL: a randomized comparative study of switch to Trizivir® compared to HAART in patients successfully treated with HAART (AZL30002) [Abstract 316]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2001
8.
ClumeckN, GoebelF, RozenbaumWSimplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.AIDS2001; 15: 151726
9.
GulickRM, RibaudoHJ, ShikumaCMACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection [Abstract 41]. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris 2003
10.
BeckerS, RachlisA, GillJSuccessful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads — a prospective, randomized, multicenter, open-label study (DMP 049) [Abstract 20]. 8th Conference on Retroviruses and Opportunistic Infections, Chicago 2001
11.
SanneI, PilieroP, SquiresKResults of a Phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.J Acquir Immune Defic Syndr2003; 32: 1829
12.
SquiresKE, ThiryA, GiordanoM. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (A1424-034) [Abstract H-1076]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002
13.
MaggioloF, AridC, GregisGPA controlled, randomized, prospective study on a once-a-day therapy for HIV infection [Poster H-163]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002
14.
DybulM, YoderC, BelsonMShort cycle intermittent HAART: a pilot study [Abstract LbOr12]. XIII International AIDS Conference, Durban 2000
15.
GogtayJA, ManekV, NayakVGA pharmacokinetic evaluation of lamivudine, stavudine and nevirapine given as a fixed combination pill versus the same three drugs given separately to healthy human volunteers [Abstract PL 8.4]. HIV 6, Glasgow 2002
16.
FischlJ, CastroL, MonroigR. Impact of directly observed therapy on long-term outcomes in HIV clinical trials [Abstract 528]. 8th Conference on Retroviruses and Opportunistic Infections, Chicago 2001
